Renal cell carcinoma (RCC) is one of the ten most common and lethal cancers in the United
States. Tumor heterogeneity and development of resistance to treatment suggest that patient …

Simple Summary Renal cell carcinoma (RCC) is common, affecting over 400,000 patients
globally each year. In limited stage disease and where surgery is a feasible therapeutic …

Molecular or immunological differences between responders and nonresponders to immune
checkpoint inhibitors (ICIs) of clear cell renal cell carcinomas (ccRCCs) remain incompletely …

The immune cells within the tumor microenvironment are considered key determinants of
response to cancer immunotherapy. Immune checkpoint blockade (ICB) has transformed the …

The introduction of targeted agents has substantially improved treatment of metastatic clear-
cell renal cell carcinoma (RCC). However, complete responses are rare and therapy is not …

Immune checkpoint blockade (ICB) results in durable disease control in a subset of patients
with advanced renal cell carcinoma (RCC), but mechanisms driving resistance are poorly …

Since the last renal cell carcinoma (RCC) issue of Hematology/Oncology Clinics of North
America in 2011, the management of this disease has changed dramatically with more than …

Cancer treatment has been revolutionized by characterizing the genomic landscape of
tumors and developing targeted therapies through The Cancer Genome Atlas (TCGA) and …

Background Immune checkpoint inhibitors and antiangiogenic agents are used for first-line
treatment of advanced papillary renal cell carcinoma (pRCC) but pRCC response rates to …

Tumor Microenvironment in Renal Cell Carcinoma: What is the Current Impact? Page 1
Commentary For reprint orders, please contact: reprints@futuremedicine.com Tumor …